Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (6388)	1/31/1999 1:00:00 PM
From: Cytokine1	Respond to of 9719

Don't know about AMLN, but 2-1-99 Investor's Bus Daily features Trimeris (TRMS -- $19.125) on The New America page. Main drug is T-20, first in a new class of drugs called fusion inhibitors. T-20 stops the AIDS virus before it passes through a cell membrane. Trimeris plans to market T-20 in combination with other approved drugs. T-20 has completed Phase II trials, and may be ready for FDA approval and marketing by 2001. A developmental-phase (another one!!) company, TRMS will not be profitable before 2001. Not a huge web site: trimeris.com